Article

HIV-related neurocognitive impairment in the HAART era.

Mount Sinai School of Medicine, Department of Neurology, Box 1052, One Gustave L. Levy Place, New York, NY 10029, USA.
Current HIV/AIDS Reports 09/2009; 6(3):146-52. DOI: 10.1007/s11904-009-0020-1
Source: PubMed

ABSTRACT Neurocognitive impairment is common in people living with HIV and AIDS. Prior to highly active antiretroviral therapy (HAART), cognitive impairment primarily affected patients with advanced disease, and was a more rapidly progressive illness. With the use of HAART, cognitive impairment improved, along with the overall health of HIV-positive patients. However, it is still a prevalent problem, even in patients with desirable CD4+ count and undetectable plasma viral load. In this review, we address the nature of HIV-related neurocognitive impairment in the HAART era, including its etiology, pathology, appropriate diagnostic tools for clinical practice and research, and rational treatment approaches.

0 Followers
 · 
120 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infection of the CNS with HIV-1 occurs rapidly after primary peripheral infection. HIV-1 can induce a wide range of neurological deficits, collectively known as HIV-1-associated neurocognitive disorders. Our previous work has shown that the selected neurotoxic effects induced by individual viral proteins, Tat and gp120, and by HIV+ supernatant are enhanced by co-exposure to morphine. This mimics co-morbid neurological effects observed in opiate-abusing HIV+ patients. Although there is a correlation between opiate drug abuse and progression of HIV-1-associated neurocognitive disorders, the mechanisms underlying interactions between HIV-1 and opiates remain obscure. Previous studies have shown that HIV-1 induces neurotoxic effects through abnormal activation of GSK3β. Interestingly, expression of GSK3β has shown to be elevated in brains of young opiate abusers indicating that GSK3β is also linked to neuropathology seen with opiate abusing patients. Thus, we hypothesize that GSK3β activation is a point of convergence for HIV- and opiate-mediated interactive neurotoxic effects. Neuronal cultures were treated with supernatant from HIV-1SF162-infected THP-1 cells, in the presence or absence of morphine and GSK3β inhibitors. Our results show that GSK3β inhibitors, including valproate and small molecule inhibitors, significantly reduce HIV-1-mediated neurotoxic outcomes, and also negate interactions with morphine that result in cell death, suggesting that GSK3β-activation is an important point of convergence and a potential therapeutic target for HIV- and opiate-mediated neurocognitive deficits.
    Molecular and Cellular Neuroscience 01/2015; 65. DOI:10.1016/j.mcn.2015.01.001 · 3.73 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The advent of highly active antiretroviral therapy has prolonged the life expectancy of HIV patients and decreased the number of adults who progress to AIDS and HIV-associated dementia. However, neurocognitive deficits remain a pronounced consequence of HIV/AIDS. HIV-1 infection targets the central nervous system in subcortical brain areas and leads to high rates of delirium, depression, opportunistic central nervous system infections, and dementia. Long-term HIV replication in the brain occurs in astrocytes and microglia, allowing the virus to hide from antiviral medication and later compromise neuronal function. The associated cognitive disturbance is linked to both viral activity and inflammatory and other mediators from these immune cells that lead to the damage associated with HIV-associated neurocognitive disorders, a general term given for these disturbances. We review the severity and prevalence of the neuropsychiatric complications of HIV including delirium, neurobehavioral impairments (depression), minor cognitive-motor dysfunction, and HIV-associated dementia.
    HIV/AIDS - Research and Palliative Care 01/2015; 7:35-47. DOI:10.2147/HIV.S39665
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study is to characterize brain gray matter volumetric changes in HIV seropositive without neurocognitive impairment and seronegative men in Asia. We investigate 36 males with HIV seropositive (mean age 34.5±9.1 years) and 33 age- and gender-matched seronegative controls (mean age 31.4±7.6 years) in Asia. The cognitive competence of 36 males with HIV seropositive has no impaired based on performance in the international HIV dementia scale. High-resolution T1-weighted magnetic resonance imaging is performed on a 3.0 T MR system using a standard 32-channel birdcage head coil. Voxel-based morphometry is used to derive volumetric measurements at the level of the individual voxel (p < 0.001, none corrected for multiple comparisons). Compared to the control group, HIV seropositive male lower gray matter volumes are found in left inferior frontal gyrus triangular part and orbital part, left superior temporal gyrus, right middle frontal gyrus and ant cingulum; significant increases gray matter volumes can be seen in Periaqueductal gray and gray around lateral ventricle. HIV infection can change the gray matter volume early without cognitive competence impaired and MR can recognize that changes.
    International Journal of Clinical and Experimental Medicine 01/2014; 7(10):3362-3369. · 1.42 Impact Factor